Table 1.
Open in new tab

Baseline characteristics of patients with acute aortic syndrome (AAS) treated with clevidipine compared to sodium nitroprusside (SNP).

Clevidipine (n=85)SNP (n=50)p Value
Clinical characteristics
Gender, male – n (%)48 (56.0%)27 (54.0%)0.858
Age, years, mean ± SD65.4±15.461.3±16.40.151
Coronary artery disease – n (%)15 (30.0%)27 (31.8%)0.850
Hypertension – n (%)73 (85.9%)46 (92.0%)0.410
HfrEF – n (%)3 (3.5%)6 (12.0%)0.076
HfpEF – n (%)3 (3.5%)0 (0.0%)NA
Atrial fibrillation – n (%)20 (23.5%)8 (16.0%)0.381
Hyperlipidemia – n (%)36 (42.4%)18 (36.0%)0.586
Smoking – n (%)27 (31.8%)18 (36.0%)0.706
Diabetes mellitus – n (%)11 (12.9%)5 (10.0%)0.784
CKD – n (%)11 (12.9%)4 (8.0%)0.572
Dialysis – n (%)0 (0.0%)1 (2.0%)0.370
Ejection fraction, mean±SD60.05±7.757.5±11.30.170
Serum creatinine, mean±SD1.45±3.61.1±0.50.380
SBP at presentation, mean±SD146.3±25.8155.5±29.90.080
DBP at presentation, mean±SD74.6±16.374.62±18.90.900
HR at presentation, mean±SD74.01±13.873.14±12.40.700
Type of aortic pathology
Type A AAD – n (%)27 (31.8%)23 (46.0%)0.139
Type B AAD – n (%)44 (51.8%)33 (66.0%)0.149
AAA – n (%)30 (35.7%)7 (14.0%)0.009
Concomitant medications
Metoprolol – n (%)73 (85.9%)42 (84.0%)0.805
Labetalol – n (%)14 (16.7%)16 (32.0%)0.053
Diltiazem – n (%)5 (5.9%)1 (2.0%)0.411
Clevidipine (n=85)SNP (n=50)p Value
Clinical characteristics
Gender, male – n (%)48 (56.0%)27 (54.0%)0.858
Age, years, mean ± SD65.4±15.461.3±16.40.151
Coronary artery disease – n (%)15 (30.0%)27 (31.8%)0.850
Hypertension – n (%)73 (85.9%)46 (92.0%)0.410
HfrEF – n (%)3 (3.5%)6 (12.0%)0.076
HfpEF – n (%)3 (3.5%)0 (0.0%)NA
Atrial fibrillation – n (%)20 (23.5%)8 (16.0%)0.381
Hyperlipidemia – n (%)36 (42.4%)18 (36.0%)0.586
Smoking – n (%)27 (31.8%)18 (36.0%)0.706
Diabetes mellitus – n (%)11 (12.9%)5 (10.0%)0.784
CKD – n (%)11 (12.9%)4 (8.0%)0.572
Dialysis – n (%)0 (0.0%)1 (2.0%)0.370
Ejection fraction, mean±SD60.05±7.757.5±11.30.170
Serum creatinine, mean±SD1.45±3.61.1±0.50.380
SBP at presentation, mean±SD146.3±25.8155.5±29.90.080
DBP at presentation, mean±SD74.6±16.374.62±18.90.900
HR at presentation, mean±SD74.01±13.873.14±12.40.700
Type of aortic pathology
Type A AAD – n (%)27 (31.8%)23 (46.0%)0.139
Type B AAD – n (%)44 (51.8%)33 (66.0%)0.149
AAA – n (%)30 (35.7%)7 (14.0%)0.009
Concomitant medications
Metoprolol – n (%)73 (85.9%)42 (84.0%)0.805
Labetalol – n (%)14 (16.7%)16 (32.0%)0.053
Diltiazem – n (%)5 (5.9%)1 (2.0%)0.411

AAA: abdominal aortic aneurysm; AAD: acute aortic dissection; CKD: chronic kidney disease; DBP: diastolic blood pressure HfpEF: heart failure with preserved ejection fraction; HfrEF: heart failure with reduced ejection fraction; HR: heart rate; SBP: systolic blood pressure; SD: standard deviation.

Table 1.
Open in new tab

Baseline characteristics of patients with acute aortic syndrome (AAS) treated with clevidipine compared to sodium nitroprusside (SNP).

Clevidipine (n=85)SNP (n=50)p Value
Clinical characteristics
Gender, male – n (%)48 (56.0%)27 (54.0%)0.858
Age, years, mean ± SD65.4±15.461.3±16.40.151
Coronary artery disease – n (%)15 (30.0%)27 (31.8%)0.850
Hypertension – n (%)73 (85.9%)46 (92.0%)0.410
HfrEF – n (%)3 (3.5%)6 (12.0%)0.076
HfpEF – n (%)3 (3.5%)0 (0.0%)NA
Atrial fibrillation – n (%)20 (23.5%)8 (16.0%)0.381
Hyperlipidemia – n (%)36 (42.4%)18 (36.0%)0.586
Smoking – n (%)27 (31.8%)18 (36.0%)0.706
Diabetes mellitus – n (%)11 (12.9%)5 (10.0%)0.784
CKD – n (%)11 (12.9%)4 (8.0%)0.572
Dialysis – n (%)0 (0.0%)1 (2.0%)0.370
Ejection fraction, mean±SD60.05±7.757.5±11.30.170
Serum creatinine, mean±SD1.45±3.61.1±0.50.380
SBP at presentation, mean±SD146.3±25.8155.5±29.90.080
DBP at presentation, mean±SD74.6±16.374.62±18.90.900
HR at presentation, mean±SD74.01±13.873.14±12.40.700
Type of aortic pathology
Type A AAD – n (%)27 (31.8%)23 (46.0%)0.139
Type B AAD – n (%)44 (51.8%)33 (66.0%)0.149
AAA – n (%)30 (35.7%)7 (14.0%)0.009
Concomitant medications
Metoprolol – n (%)73 (85.9%)42 (84.0%)0.805
Labetalol – n (%)14 (16.7%)16 (32.0%)0.053
Diltiazem – n (%)5 (5.9%)1 (2.0%)0.411
Clevidipine (n=85)SNP (n=50)p Value
Clinical characteristics
Gender, male – n (%)48 (56.0%)27 (54.0%)0.858
Age, years, mean ± SD65.4±15.461.3±16.40.151
Coronary artery disease – n (%)15 (30.0%)27 (31.8%)0.850
Hypertension – n (%)73 (85.9%)46 (92.0%)0.410
HfrEF – n (%)3 (3.5%)6 (12.0%)0.076
HfpEF – n (%)3 (3.5%)0 (0.0%)NA
Atrial fibrillation – n (%)20 (23.5%)8 (16.0%)0.381
Hyperlipidemia – n (%)36 (42.4%)18 (36.0%)0.586
Smoking – n (%)27 (31.8%)18 (36.0%)0.706
Diabetes mellitus – n (%)11 (12.9%)5 (10.0%)0.784
CKD – n (%)11 (12.9%)4 (8.0%)0.572
Dialysis – n (%)0 (0.0%)1 (2.0%)0.370
Ejection fraction, mean±SD60.05±7.757.5±11.30.170
Serum creatinine, mean±SD1.45±3.61.1±0.50.380
SBP at presentation, mean±SD146.3±25.8155.5±29.90.080
DBP at presentation, mean±SD74.6±16.374.62±18.90.900
HR at presentation, mean±SD74.01±13.873.14±12.40.700
Type of aortic pathology
Type A AAD – n (%)27 (31.8%)23 (46.0%)0.139
Type B AAD – n (%)44 (51.8%)33 (66.0%)0.149
AAA – n (%)30 (35.7%)7 (14.0%)0.009
Concomitant medications
Metoprolol – n (%)73 (85.9%)42 (84.0%)0.805
Labetalol – n (%)14 (16.7%)16 (32.0%)0.053
Diltiazem – n (%)5 (5.9%)1 (2.0%)0.411

AAA: abdominal aortic aneurysm; AAD: acute aortic dissection; CKD: chronic kidney disease; DBP: diastolic blood pressure HfpEF: heart failure with preserved ejection fraction; HfrEF: heart failure with reduced ejection fraction; HR: heart rate; SBP: systolic blood pressure; SD: standard deviation.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close